Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer
Phytomedicine · 2024
DOI: 10.1016/j.phymed.2024.155804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Jiaqiang Bo und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and School of Life Science and Technology, China Pharmaceutical University, Nanjing, China; School of Life …. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Thyroid Cancer, Papillary, Proto-Oncogene Proteins c-akt, Signal Transduction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: China Pharmaceutical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Papillary thyroid carcinoma (PTC) is an endocrine malignant tumor of the head and neck. Surgery and chemotherapy are PTC treatments, but have adverse effects. Exploration of new non-toxic anti-PTC drugs for PTC treatment is an unmet need. METHODS: We aimed to identify anti-PTC drugs that could inhibit PTC-cell proliferation through high-throughput screening of a library of well-characterized naturally occurring small-molecule compounds. Then, the anti-PTC function of rhodiolin was validated by in vitro cell models and xenograft tumor models RESULTS: We initially demonstrated that rhodiolin inhibited the growth and induced the apoptosis of PTC cells significantly in vitro and in vivo. At the metabolic level, rhodiolin blocked glycolysis through glucose 6-phosphate isomerase (GPI), which suggested that glycolytic inhibition may be involved in mediating the anti-PTC function of rhodiolin. Transcriptomics analysis combined with bioinformatics analysis identified rhodiolin treatment to inhibit phosphorylation of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway. Collectively, our findings demonstrated that rhodiolin inhibited the proliferation and induced the apoptosis of PTC cells by blocking glycolysis through the glycolytic enzyme GPI, thereby inhibiting phosphorylation of the PI3K/Akt/mTOR signaling pathway. CONCLUSION: Our study demonstrates the potential use of rhodiolin in inhibiting the proliferation and inducing the apoptosis of PTC cells. Inhibition of phosphorylation of the PI3K/Akt/mTOR signaling pathway mediated by GPI plays an extremely important part in the ant-PTC function of rhodiolin. These results suggest that rhodiolin is a promising drug in the treatment of PTC progression. Our results provide a novel target and cell signaling pathway for PTC therapy from the perspective of energy metabolism, which could provide new perspectives and new drug choices for PTC therapy. In addition to that, our study will help to make up for the lack of drug research for PTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and School of Life Science and Technology, China Pharmaceutical University, Nanjing, China; School of Life Science and Technology, China Pharmaceutical University, Nanjing, Chin…
Förderung
- China Pharmaceutical University
- National Natural Science Foundation of China
Zitieren
APA
Bo, J., Mao, S., Yang, J., Wang, L., Zheng, J., Zhang, C., Song, M., Chen, S., & Liu, C. (2024). Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.155804
Vancouver
Bo J, Mao S, Yang J, Wang L, Zheng J, Zhang C, et al. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. Phytomedicine. 2024. doi:10.1016/j.phymed.2024.155804
BibTeX
@article{Bo2024,
author = {Bo, Jiaqiang and Mao, Shuyu and Yang, Jie and Wang, Li and Zheng, Jia and Zhang, Chunyu and Song, Mingming and Chen, Siyu and Liu, Chang},
title = {Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer},
journal = {Phytomedicine},
year = {2024},
doi = {10.1016/j.phymed.2024.155804}
}
EUVIMED